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Abstract
Introduction Endothelin (EDN) signalling plays a crucial role in
cell differentiation, proliferation and migration processes. There
is compelling evidence that altered EDN signalling is involved in
carcinogenesis by modulating cell survival and promoting
invasiveness. To date, most reports have focused on the
oncogenic potential of EDN1 and EDN2, both of which are
overexpressed in various tumour entities. Here, we aimed at a
first comprehensive analysis on EDN3 expression and its
implication in human breast cancer.
Methods EDN3 mRNA expression was assessed by Northern
blotting in normal human tissues (n = 9) as well as in matched
pairs of normal and tumourous tissues from breast specimens (n
= 50). EDN3 mRNA expression in breast cancer was further
validated by real-time polymerase chain reaction (PCR) (n = 77).
A tissue microarray was used to study EDN3 protein expression
in breast carcinoma (n = 150) and normal breast epithelium (n
= 44). EDN3  promoter methylation was analysed by
methylation-specific PCR in breast cell lines (n = 6) before and
after demethylating treatment, normal breast tissues (n = 17)
and primary breast carcinomas (n = 128). EDN3 expression and
methylation data were statistically correlated with clinical patient
characteristics and patient outcome.
Results Loss of EDN3 mRNA expression in breast cancer, as
initially detected by array-based expression profiling, could be
confirmed by Northern blot analysis (> 2-fold loss in 96%) and
real-time PCR (> 2-fold loss in 78%). Attenuated EDN3
expression in breast carcinoma was also evident at the protein
level (45%) in association with adverse patient outcome in
univariate (P = 0.022) and multivariate (hazard ratio 2.0; P =
0.025) analyses. Hypermethylation of the EDN3 promoter could
be identified as the predominant mechanism leading to gene
silencing. Reversion of the epigenetic lock by 5-aza-2'-
deoxycytidine and trichostatin A resulted in EDN3 mRNA re-
expression  in vitro. Furthermore, EDN3  promoter
hypermethylation was detected in 70% of primary breast
carcinomas with significant association to loss of EDN3 mRNA
expression (P = 0.005), whilst normal matched breast tissues
revealed no EDN3 promoter methylation.
Conclusions  EDN3  is a frequent target of epigenetic
inactivation in human breast cancer, potentially contributing to
imbalanced EDN signalling commonly found in this disease. The
clinical implication supports the view that EDN3, in contrast to
EDN1 and EDN2, may act as natural tumour suppressor in the
human mammary gland.
bp: base pair(s); CI: confidence interval; CPA: cancer profiling array; CpG: cytosine-phosphate-guanine dinucleotide; CSS: breast cancer-specific 
survival; CT: cycle threshold; DAC: 5-aza-2'-deoxycytidine; DFS: disease-free survival; DNMT: DNA methyltransferase; EDN: endothelin; EDNR: 
endothelin receptor; ET-axis: endothelin axis; FC2: fold change of greater than 2; FFPE: formalin-fixed paraffin-embedded; GAPDH: glyceraldehyde-
3-phosphate-dehydrogenase; HDAC: histone acetyltransferase; IHC: immunohistochemistry; IRS: immunoreactivity score; MSP: methylation-specific 
polymerase chain reaction; MTN: multiple-tissue Northern (blot); PCR: polymerase chain reaction; SD: standard deviation; TMA: tissue microarray; 
TSA: trichostatin A.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
Page 2 of 18
(page number not for citation purposes)
Introduction
Endothelins (EDNs) are widely expressed cytokines in a variety
of human tissues, including brain, skeletal muscle, pancreas,
small intestine, testis and colon [1]. They constitute a family of
small, vasoactive, 21-amino acid peptides referred to as
EDN1, EDN2 and EDN3 [2]. EDNs are synthesised as large
precursor proteins that are post-translationally cleaved to the
biologically active 21-amino acid form [3]. They are involved in
fundamental cellular networks like cell proliferation, migration
and differentiation processes [4,5] by interacting with their
corresponding cell surface-bound EDN-A (EDNRA) and EDN-
B (EDNRB) receptors in an autocrine and also a paracrine
manner [6-8]. A balanced regulation of this EDNRA/EDNRB
interplay – also referred to as the endothelin axis (ET-axis)- is
essential for, for example, homing processes to tissue destina-
tions, where cells differentiate into numerous lineages such as
the peripheral nervous system, structural and connective tis-
sue components, cardiac cells or pigment-producing melano-
cytes [9].
There is now compelling evidence that imbalanced regulation
of the ET-axis is implicated in human carcinogenesis, tumour
progression and neo-angiogenesis [8,10-12]. During malig-
nant cell transformation, the basic tissue architecture, which is
maintained by basement membrane delineation, becomes dis-
rupted [8]. This indicates the presence of crucial mediators
that trigger the exchange of growth factors between the par-
ticipating cells at the tumour invasion field. Essentially, such
growth factor release is thought to enhance invasiveness,
stimulate cell migration and promote neo-vascularisation [8].
Multiple signal transduction pathways are affected down-
stream from EDNRA/B. In the case of interaction of EDNs with
EDNRA, a pertussis toxin-insensitive G protein becomes acti-
vated and promotes stimulation of phospholipase C, resulting
in the transactivation of the mitogen-activated protein kinase
pathway [13]. Second, EDN1 and EDN2 binding to EDNRA
can activate p125 focal adhesion kinase and paxillin, both of
which have been associated with increased tumour cell inva-
sion. Moreover, EDNs are able to transduce the activation of
anti-apoptotic signals through phosphatidylinositol-3-kinase
and to stimulate neo-angiogenesis through vascular endothe-
lial growth factor signalling [14]. These multiple ET-axis path-
way implications may explain its various impairments of normal
cellular integrity in case of an aberrant shift from balanced to
imbalanced EDN signalling.
Previously, EDN1 and EDN2 were found to be commonly over-
expressed in a broad range of human tumour entities
[8,11,12]. So far, most reports have focused on the role of
EDN1 binding to EDNRA and its effects on tumour growth and
neo-angiogenesis [8,11,13,15]. A role similar to that of EDN1
has been described for EDN2 in human breast cancer.
Increased expression of EDN1 and EDN2, but not of EDN3,
induced chemotaxis of breast cancer cells and increased
tumour cell invasion through the basement membrane [4],
although conflicting results have been reported by others [16].
In line with this, previous reports described a compensatory
effect of EDN3 by negatively modulating the effects trans-
duced by EDN1 [17] and demonstrated that downregulation
of EDN3 is associated with upregulation of EDN1 in human
tissues [18].
However, a comprehensive analysis of EDN3 expression in
normal and cancerous breast tissues and its potential implica-
tion in human breast cancer has not been published so far. In
our study, we investigated for the first time EDN3 mRNA and
protein expression in a large number of primary breast tissues
and breast cell lines. Furthermore, we identified the molecular
mechanism by which EDN3 expression is deregulated in
breast carcinomas.
Materials and methods
Cryo-conserved clinical patient material
Cryo-conserved clinical samples were obtained from breast
cancer patients treated by primary surgery at the University
Hospitals of Aachen, Düsseldorf and Regensburg. Patients
receiving neo-adjuvant chemotherapy and patients with recur-
rent breast cancer were excluded. Resected tissue was snap-
frozen in liquid nitrogen immediately after surgery. Only sam-
ples containing more than 70% of tumourous cells in haema-
toxylin/eosin-stained control sections were further processed
(n = 128). For 17 samples, macroscopically normal breast tis-
sues containing at least 30% of epithelial cells were available.
In all cases, two board-certified pathologists agreed on the
diagnosis of breast cancer. Tumour histology was determined
according to the criteria of the World Health Organization
(2003), whereas disease stage was assessed according to
the UICC (Union Internationale contre le Cancer) [19].
Tumours were graded according to Bloom and Richardson, as
modified by Elston and Ellis [20]. All patients gave informed
consent for retention and analysis of their tissue for research
purposes, and the institutional review boards of the participat-
ing centres approved the study. For 98 patients, follow-up
data were available with a median time of 63 months (range 1
to 124 months). Patient characteristics of this cohort are sum-
marised in Table 1.
Formalin-fixed paraffin-embedded clinical patient 
material
A tissue microarray (TMA) was created as described previ-
ously by Bubendorf and colleagues [21]. The formalin-fixed
paraffin-embedded (FFPE) tissue sections were obtained from
the archive of the Institute of Pathology, University of Regens-
burg, Germany. In all cases, two board-certified pathologists
agreed on the diagnosis of breast cancer. Patients receiving
neo-adjuvant chemotherapy and patients with recurrent breast
cancer were excluded. All patients gave informed consent for
retention and analysis of their tissues for research purposes,
and the institutional review board of the participating centre
approved the study. The TMA consisted of 150 primaryAvailable online http://breast-cancer-research.com/content/11/3/R34
Page 3 of 18
(page number not for citation purposes)
tumours from malignant breast tissue and 44 normal breast
specimens. Follow-up data were available for 146 patients
with a median time of 77 months (range 1 to 148 months).
Detailed tumour characteristics of this cohort are listed in
Table 2.
Breast cell lines
The non-cancerous breast cell lines MCF10A and MCF12A as
well as the cancerous breast cell lines MCF7, SKBR3, MDA-
MB231 and BT20 were obtained from the American Type Cul-
ture Collection (Manassas, VA, USA) and cultured as recom-
mended by the vendor.
Northern blot expression analysis
Expression of EDN3  mRNA in various human tissues was
tested using the commercial multiple-tissue Northern (MTN)
blots I and II (Clontech, Heidelberg, Germany), containing 2
μg of poly A+ RNA per lane from 16 different human tissues
(that is, blot I: heart, whole brain, placenta, lung, liver, skeletal
muscle, kidney and pancreas; blot II: spleen, thymus, prostate,
testis, ovary, small intestine, colon [no mucosa] and peripheral
blood lymphocytes). Hybridisation was performed using 25 ng
of an EDN3-specific 722-base pair (bp) polymerase chain
reaction (PCR) product derived from (GenBank accession
number NM_000114.2) (position: 968 to 1,707), which was
verified by sequence analysis. 32P-labelling of the DNA probe
was achieved using the Megaprime DNA Labeling System
(Amersham Biosciences, now part of GE Healthcare, Little
Chalfont, Buckinghamshire, UK), and hybridisation was per-
formed in accordance with the recommendation the manufac-
turer. The cancer profiling array (CPA) I (Clontech) is a
matched tumour/normal expression array consisting of cDNA
synthesised from 50 breast carcinomas, 50 normal breast tis-
sues and 3 breast cancer lymph node metastasis specimens.
Hybridisation was performed in accordance with the recom-
mendations the manufacturer as described above for the MTN
blots. Hybridisation signals of both, MTN blots and the CPA,
were evaluated by use of a STORM-860 phosphoimager
(Molecular Dynamics, now part of GE Healthcare). Intensity
ratios were calculated after normalising signals against the
background.
Nucleic acid extraction
Frozen tissue samples and cell line pellets were dissolved in
lysis buffer for subsequent DNA isolation using the QIAmp
DNA Mini kit (Qiagen, Hilden, Germany) or for total RNA iso-
lation by using TRIzol reagent (Invitrogen Corporation,
Carlsbad, CA, USA) in accordance with the protocol supplied
by the manufacturers.
Reverse transcription of RNA
Of the extracted total RNA, 1 μg was reverse-transcribed
using the Reverse Transcription System (Promega Corpora-
tion, Madison, WI, USA) by applying a mix of oligo-dT and
pdN(6)-hexamer primers (1:2). The obtained cDNA was diluted
Table 1
Clinicopathological parameters of cryo-conserved breast 
cancer specimens (n = 128)
Variables Numbera Percentage
Clinicopathological factors
Age at diagnosisb
< 58 years 64 50.0
≥ 58 years 64 50.0
Tumour sizec
pT1 44 34.4
pT2 55 43.0
pT3 6 4.7
pT4 11 8.6
pTx 12 9.4
Lymph node statusc
pN0 57 44.5
pN1–3 51 39.8
pNx 20 15.6
Histological grade
G1 10 7.8
G2 58 45.3
G3 49 38.3
NA 11 8.6
Histological type
Ductal 103 80.5
Lobular 15 11.7
Other 6 4.7
NA 4 3.1
Immunohistochemistry
Oestrogen receptor
Negative (IRSd ≤ 2) 33 25.8
Positive (IRS > 2) 85 66.4
NA 10 7.8
Progesterone receptor
Negative (IRSd ≤ 2) 33 25.8
Positive (IRS > 2) 85 66.4
NA 10 7.8
Due to rounding, percentages may not sum to 100. aOnly female 
patients with primary invasive breast cancer were included. bMedian 
58 years, range 28 to 87 years. cAccording to the UICC (Union 
Internationale contre le Cancer): TNM Classification of Malignant 
Tumours [19].dImmunoreactivity score (IRS) according to Remmele 
and Stegner [24]. NA, information not available.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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(20 ng/μL) and test-amplified using intron-spanning primers
for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH).
Primer sequences are provided in Table 3. PCRs were initi-
ated as 'Hot Start' PCR at 95°C for 5 minutes and a hold at
80°C before the addition of 1 unit of GoTaq DNA polymerase
(Promega Corporation). Cycle conditions were 95°C for 5
minutes, 35 cycles of 95°C for 1 minute, 60°C for 1 minute,
72°C for 1 minute and a final extension at 72°C for 10 minutes.
PCR analyses were carried out in a PTC-200 cycler (Bio-Rad
Laboratories, Inc., formerly MJ Research, Hercules, CA, USA).
Amplificates were evaluated under ultraviolet light after 2%
agarose gel electrophoresis containing ethidium bromide.
Only samples yielding a specific 510-bp amplificate were fur-
ther subjected to real-time PCR.
Semi-quantitative real-time polymerase chain reaction
The Roche LightCycler system was used for semi-quantitative
light cycler analysis in combination with the LightCycler DNA
Master SYBR Green I Kit (Roche, Mannheim, Germany) as
previously described [22]. Gene expression was quantified by
the comparative cycle threshold (CT) method, normalising CT
values to the housekeeping gene GAPDH and calculating rel-
ative expression values [23]. A commercially available normal
breast cDNA pool (Clontech) was used as a breast reference
standard. Primer sequences are listed in Table 3.
Immunohistochemistry
Paraffin sections of 2 μm were deparaffinised in xylene fol-
lowed by rehydration in a decreasing ethanol series. Antigen
retrieval was performed by pre-treatment in boiling citrate
buffer (pH 6.0) in a microwave oven for 30 minutes (200 W).
Immunohistochemistry (IHC) was performed using an NEXES
Immuno Stainer (Ventana Medical Systems, Inc., Tucson, AZ,
USA) in accordance with the specifications of the manufac-
turer. A goat polyclonal EDN3-specific antibody (sc-21628;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was
used in a 1:150 dilution by using the ChemMate Envision Kit
(DAKO, Hamburg, Germany). Counterstaining was performed
by using Mayer's haematoxylin. The incubation with primary
antibodies was omitted in negative controls. All analysed sam-
ples were stained without the knowledge of histopathological
data. Cytoplasmic protein staining was semi-quantitatively
scored by an experienced breast pathologist according to the
well-established scoring system developed by Remmele and
Stegner [24]. To verify staining specificity, the primary anti-
body was incubated with a 200 molar excess of blocking pep-
tide (sc-21628 P; Santa Cruz Biotechnology, Inc.) for 2 hours
prior to its application on test samples.
CpG island prediction
EDN1,  EDN2  and  EDN3  genomic nucleotide sequences
were taken from the Ensembl database and analysed for pro-
moter CpG (cytosine-phosphate-guanine dinucleotide)
islands in accordance with the method of Li and Dahiya [25].
A fragment of 2 kb in size, beginning 1 kb 5'-upstream from the
Table 2
Clinicopathological parameters of formalin-fixed paraffin-
embedded breast cancer specimens (n = 150)
Variables Numbera Percentage
Clinicopathological factors
Age at diagnosisb
≤ 59 years 83 55.3
> 59 years 67 44.7
Tumour sizec
pT1 48 32.0
pT2 71 47.3
pT3 9 6.0
pT4 20 13.3
pTx 2 1.3
Lymph node statusc
pN0 67 44.7
pN1 35 23.3
pN2 25 16.7
pN3 20 13.3
pNx 3 2.0
Histological grade
G1 13 8.7
G2 70 46.7
G3 66 44.0
NA 1 0.7
Histological type
Ductal 122 81.3
Lobular 12 18.0
Other 16 10.7
Tumour focality
Unifocal 130 86.7
Multifocal 19 12.7
NA 1 0.7
Immunohistochemistry
Oestrogen receptor
Negative (IRSd ≤ 2) 38 25.3
Positive (IRS > 2) 83 55.3
NA 29 19.3
Progesterone receptor
Negative (IRSd ≤ 2) 85 56.7
Positive (IRS > 2) 40 26.7
NA 25 16.7
Her2 status
Negative (DAKO score 0; 1+) 105 70.0
Positive (DAKO score 2+; 3+) 23 15.3
NA 22 14.7
Due to rounding, percentages may not sum to 100. aOnly female 
patients with primary invasive breast cancer were included. bMedian 
59 years, range 29 to 82 years. cAccording to the UICC (Union 
Internationale contre le Cancer): TNM Classification of Malignant 
Tumours [19]. dImmunoreactivity score (IRS) according to Remmele 
and Stegner [24]. NA, information not available.Available online http://breast-cancer-research.com/content/11/3/R34
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annotated transcription start site (TSS) and ending 1 kb 3'-
downstream, was analysed by applying the following criteria:
island size of greater than 200 bp, guanine/cytosine content of
greater than 60% and observed/expected CpG ratio of
greater than 0.6.
Bisulphite modification and methylation-specific 
polymerase chain reaction
Of the genomic DNA, 1 μg was bisulphite-modified using the
EZ DNA Methylation Kit (Zymo Research Corporation,
Orange, CA, USA) and eluted in 20 μL of Tris buffer (10 mM).
Methylation-specific PCR (MSP) was performed in accord-
ance with the method of Herman and colleagues [26]. One
microlitre of bisulphite-treated DNA was amplified using MSP
primers that specifically recognise either the unmethylated or
methylated EDN3 promoter sequence after bisulphite conver-
sion (Table 3). To achieve high accuracy, each primer was
designed to cover three CpG sites of template DNA. Commer-
cially available universal poly-methylated DNA and unmethyl-
ated DNA (EpiTect Control DNA; Qiagen) were used as
positive controls for methylated and unmethylated EDN3
sequences, respectively. MSP products were visualised under
ultraviolet light after 3% low-range ultra agarose gel electro-
phoresis containing ethidium bromide (Bio-Rad Laboratories,
Inc.). Promoter methylation status was interpreted in a binary
qualitative fashion.
In vitro demethylating treatment
Cells were seeded at a density of 3 × 104 cells/cm2 in a six-
well plate. The demethylation agent 5-aza-2'-deoxycytidine
(DAC) (Sigma-Aldrich, Deisenheim, Germany) was added to a
final concentration of 1 μM in fresh medium at days 1, 2 and 3
Table 3
Oligonucleotide primers used in this study
Sequence (5'↔3') TA, °C Cycles Product, base pairs
RT-PCR
GAPDH
Forward: TGGTCACCAGGGCTGCTT 60 35 510
Reverse: GTCTTCTGGGTGGCAGTGAT
Real-time PCR
GAPDH
Forward: GAAGGTGAAGGTCGGAGTCA 58 40 108
Reverse: TGGACTCCACGACGTACTCA
EDN1
Forward: GCTCGTCCCTGATGGATAAA 58 40 216
Reverse: TTCCTGCTTGGCAAAAATTC
EDN2
Forward: TTGGACATCATCTGGGTGAA 58 40 229
Reverse: CTGTAGTGGCCCCTGTCTTG
EDN3
Forward: ATTGCCACCTGGACATCATT 58 40 179
Reverse: GCAGGCCTTGTCATATCTCC
Methylation-specific PCR
EDN3-U
Forward: TTTGGGAGGTGATTTTTAGTGTGTTT 60 35 144
Reverse: ACCCATCCCTACACAAAACTAACCA
EDN3-M
Forward: TGGGAGGCGATTTTTAGTGCGTTC 60 35 140
Reverse: CCATCCCTACGCGAAACTAACCG
EDN, endothelin; EDN3-M, endothelin-3 methylated; EDN3-U, endothelin-3 unmethylated; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; 
PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; TA, annealing temperature.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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after seeding. Additionally, cells were exposed to 300 nM tri-
chostatin A (TSA) (Sigma-Aldrich) on day 3 for 24 hours. Con-
trol cells without DAC/TSA were supplied with fresh medium
on days 1, 2 and 3. DNA and RNA were extracted on day 4 as
mentioned above.
Statistical evaluations
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used
for statistical analyses. All tests were performed two-tailed,
and P values of below 0.05 were considered statistically sig-
nificant. The non-parametric Mann-Whitney U  test and the
Student t test (paired and unpaired) were used to compare
expression results between cancer tissues and normal tissues
or between EDN3 mRNA expression and EDN3 methylation
status. Contingency table analysis and Fisher exact tests were
used to study the statistical association between clinicopatho-
logical factors and EDN3 protein expression or EDN3 pro-
moter methylation status. Survival curves comparing patients
with or without any of the factors were calculated using the
Kaplan-Meier method, with significance evaluated by log-rank
statistics. Breast cancer-specific survival (CSS) was meas-
ured from the day of surgery until tumour-related death and
was censored for patients alive at last contact or in case of
death unrelated to the tumour. Disease-free survival (DFS)
was measured from surgery until disease relapse and cen-
sored for patients alive without evidence of relapse at the last
follow-up. For EDN3 protein expression, a multivariate Cox
proportional hazard model was employed to assess the rela-
tive risks on patient CSS and to test for independent prognos-
tic relevance of clinical/investigational factors. Only patients
for whom the status of all selected variables was known were
included in the proportional hazard model (n = 121). The limit
for reverse-selection procedures was P = 0.2. The proportion-
ality assumption for all variables was assessed with log-nega-
tive-log survival distribution functions. For analyses, the
following variables were categorised into binary values: small-
sized (pT1) versus large-sized (pT2 to pT4), node-negative
(pN0) versus node-positive (pN1 to pN3) and low-grade (G1
and G2) versus high-grade (G3) tumours.
Results
EDN3 mRNA is differentially expressed in human breast 
cancer
As previously reported, we performed in silico Northern blot
analysis and RNA array-based expression profiling to identify
novel candidate genes differentially expressed in human
breast cancer [27,28]. In the latter approach, EDN3  was
detected as one of the most frequently downregulated genes,
showing substantial expression loss in 63% of breast carcino-
mas (data not shown). Therefore, we started a detailed analy-
sis on EDN3 expression and its potential implication in human
breast cancer.
An initial Northern blot analysis of normal human tissues dem-
onstrates that EDN3 mRNA is abundantly expressed in a vari-
ety of non-malignant tissues, including pancreas, spleen,
prostate, testis, small intestine and colon, with two major
mRNA transcripts of 2.4 and 2.7 kb in size (Figure 1a). A
breast cancer dot blot cDNA array was then hybridised with
the same EDN3-specific probe. This showed a clear loss of
EDN3 mRNA expression, as defined by a fold change (tumour
versus normal) of greater than 2 (FC2), in 96% (48 of 50) of
the analysed breast carcinoma samples and also in all three
corresponding lymph node metastases (P < 0.001) (Figure
1b, c). To confirm this result, EDN3 mRNA expression was
also assessed by real-time PCR in a set of 77 breast tumour
tissues and 17 corresponding normal breast tissues. In breast
carcinomas, downregulation of EDN3  expression by FC2
could be detected in 60 of 77 cases (78%; median: 21-fold)
as compared with the normal breast reference standard (Fig-
ure 1d). This downregulation was still evident when comparing
EDN3 expression among all tumour and normal breast tissues
as illustrated by box plot analysis (P < 0.001) (Figure 1e) as
well as when comparing fold changes of EDN3 expression
among the 17 matched pairs (Figure 1f). In the latter analysis,
14 of 17 pairs (82%) showed EDN3 downregulation by FC2,
with a median expression change of 13-fold.
Differential EDN3 protein expression in human breast 
cancer
To analyse whether loss of EDN3 expression in breast cancer
is also evident on the protein level, we used a TMA comprising
150 invasive breast carcinomas and 44 normal breast tissue
specimens. The specificity of the antibody applied was deter-
mined by the simultaneous use of blocking peptide against
EDN3 in normal breast samples, which showed a clear
decrease of overall EDN3 staining (Additional data file 1).
EDN3 protein was clearly detectable in 75.0% (32 of 44) of
normal breast tissue samples analysed (Figure 2a, b), as
defined by an immunoreactivity score (IRS) of at least 8. The
mean normal expression was determined to be IRS = 8.2 (±
3.8 standard deviations [SDs]). Expression was predominantly
localised in luminal and basal epithelial cells of the normal
breast and was weakly detectable in normal stromal compart-
ments. In contrast, invasive breast carcinomas showed com-
plete loss or reduced EDN3 expression (IRS < 8) in 45.3%
(68 of 150) of cases (Figure 2c, d) and abundant EDN3
expression in 54.7% (82 of 159) (Figure 2e, f). Mean EDN3
expression in invasive breast carcinomas was determined to
be IRS = 6.7 (± 4.0 SDs). EDN3 protein was rarely observed
in tumour stroma (that is, was detectable only in those stromal
cells adjacent to tumour cells with strong EDN3 expression).
The difference of EDN3 expression between tumours and nor-
mal breast tissues was statistically significant (Mann-Whitney
U test: P = 0.037; Student unpaired t test: P = 0.039).
Loss of EDN3 expression is associated with adverse 
patient outcome in human breast cancer
To investigate a potential clinical relevance of EDN3 in breast
cancer, we first analysed whether EDN3 protein expression isAvailable online http://breast-cancer-research.com/content/11/3/R34
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associated with clinicopathological parameters. In a bivariate
analysis, differential EDN3 expression was not associated with
patient age at diagnosis, tumour size, lymph node metastasis,
histological grade, histological type, tumour focality or oestro-
gen or progesterone receptor status (Table 4). Interestingly, in
a univariate survival analysis, we found a significant associa-
tion between low EDN3 expression and unfavourable CSS (P
= 0.022) (Figure 2g and Table 5). Patients with low EDN3
expression in the tumour had a mean CSS of 99 months (95%
confidence interval [CI] 85 to 113 months) as compared with
patients with tumours showing high EDN3 expression, which
had a prolonged mean CSS of 116 months (95% CI 106 to
126 months). The visual impression of the Kaplan-Meier
curves suggests also an association of EDN3 expression with
Figure 1
Differential expression of EDN3 mRNA in human breast cancer Differential expression of EDN3 mRNA in human breast cancer. (a) A multiple tissue Northern blot hybridised with an EDN3-specific probe indicates 
ubiquitous expression of EDN3 mRNA in a variety of normal tissue types. In some tissues, both major EDN3 transcript variants are expressed (2.4 
and 2.7 kb). (b) The same probe was hybridised to a breast cancer array containing cDNA pairs from 50 breast carcinoma tissues (T), 50 matched 
normal breast tissues (N) and 3 metastatic tissues. The outlined groups represent matched pairs, including the metastatic deposit, and consecutive 
numbers indicate specimen spots on the array. (c) Box plot demonstrating significant downregulation of EDN3 expression between normal and 
tumourous breast tissues (P < 0.001, Student paired t test; extreme value of specimen #29 omitted). Horizontal lines indicate group medians, and 
boxes indicate 25% to 75% quartiles, range, peak and minimum. (d) Real-time polymerase chain reaction analysis demonstrated loss of EDN3 
expression in 78% of breast carcinomas by FC2 (fold change of greater than 2) (black bars) whilst 22% showed no deregulation (grey bars). (e) Box 
plot demonstrating the different distributions of EDN3 expression among normal breast tissues and breast carcinomas (P < 0.001, Mann-Whitney U 
test). Horizontal lines indicate group medians, and boxes indicate 25% to 75% quartiles, range, peak and minimum. (f) Fold changes of EDN3 
expression in 17 matched pairs of normal breast and breast carcinoma samples revealed loss of expression in 13 cases (76%) and a median expres-
sion change of 13-fold. EDN3, endothelin-3.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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DFS (Figure 2h), but this was statistically not significant (P =
0.167) (Table 5). Next, we performed a multivariate Cox
regression analysis to test for independent significance of
EDN3 expression as a prognostic factor in patient CSS (Table
6). Patient age at diagnosis, tumour size, lymph node metasta-
sis, histological grade and EDN3 expression were included in
the model. After reverse selection, patient age, lymph node
status, grade and EDN3 expression remained significant in the
Cox model, with low EDN3 expression displaying a twofold
elevated risk of dying from breast cancer (hazard ratio 1.98,
95% CI 1.09 to 3.61; P = 0.025).
Loss of EDN3 mRNA expression in breast cancer cell 
lines
The NH2-terminal peptide structure of EDN3 differs consider-
ably in essential amino acids between residues 2 and residues
4 to 7 from those of EDN1 and EDN2 (Figure 3a). This region
bulges out of the basic EDN structure and has been reported
to represent a major domain for binding specificity to EDN
Figure 2
Differential EDN3 protein expression in human breast cancer and its clinical relevance Differential EDN3 protein expression in human breast cancer and its clinical relevance. (a) Abundant EDN3 protein expression in normal breast epi-
thelium. (b) Magnification of specimen shown in (a). (c) Representative invasive-ductal carcinoma showing moderate EDN3 protein expression. (d) 
Magnification of specimen shown in (c). (e) Representative invasive-ductal carcinoma with substantial loss of EDN3 protein expression. (f) Magnifi-
cation of specimen shown in (e). Kaplan-Meier curves indicating that retaining high EDN3 protein expression (immunoreactivity score of at least 8) in 
the tumour is significantly associated with more favourable (g) breast cancer-specific survival (P = 0.022, log-rank test) but not (h) disease-free sur-
vival. Magnifications: ×100 (a, c, e), ×200 (b, d, f). EDN3, endothelin-3.Available online http://breast-cancer-research.com/content/11/3/R34
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receptors and thus is critical in EDN signalling activity [29].
Because we found that EDN3 expression is frequently lost in
breast cancer tissues, we next compared EDN1, EDN2 and
EDN3 mRNA expression in breast cell lines in parallel. EDN1
was much more strongly expressed in all cancerous cell lines
(MCF7, SKBR3, MDA-MB231 and BT20) than in non-cancer-
ous MCF12A cells (Figure 3b), showing a mean upregulation
of 13.9-fold (± 7.8 SDs). EDN2 was more strongly expressed
in SKBR3 cells but less expressed in MCF7, MDA-MB231
and BT20 as compared with MCF12A cells. EDN3 expres-
sion, however, was clearly downregulated in all cancerous cell
lines as compared with non-cancerous cells, revealing a mean
expression of 0.008 (± 0.009 SDs) of that found in MCF12A
cells (set to 1). Therefore, upregulation of EDN1 appears to
Table 4
Clinicopathological factors in relation to EDN3 protein expression
EDN3 expression
Variables Numbera Low (IRS < 8) High (IRS ≥ 8) P valueb
Clinicopathological factors
Age at diagnosis
≤ 59 years 83 36 47 0.632
> 59 years 67 32 35
Tumour sizec
pT1 48 21 27 0.728
pT2 to pT4 100 47 53
Lymph node statusc
pN0 67 29 38 0.742
pN1 to pN3 80 37 43
Histological grade
G1 and G2 83 35 48 0.408
G3 66 33 33
Histological type
Ductal 122 53 69 0.385
Lobular 12 5 7
Other 16 10 6
Tumour focality
Unifocal 130 61 69 0.467
Multifocal 19 7 12
Oestrogen receptor
Negative (IRSd ≤ 2) 38 19 19 0.698
Positive (IRS > 2) 83 45 38
Progesterone receptor
Negative (IRSd ≤ 2) 85 41 44 0.704
Positive (IRS > 2) 40 21 19
Her2 status
Negative (IHC: 0; 1+) 105 46 59 0.169
Positive (IHC: 2+; 3+) 23 14 9
aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union 
Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].dImmunoreactivity score (IRS) according to Remmele and 
Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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Table 5
Clinicopathological factors in relation to disease-free and breast cancer-specific survival
Disease-free survival Breast cancer-specific survival
Numbera Events P valueb Numbera Events P valueb
Variables
Clinicopathological factors
Age at diagnosis
≤ 59 years 83 28 0.163 83 19 0.005c
> 59 years 63 25 67 29
Tumour sized
pT1 47 11 0.007c 48 9 0.013c
pT2 to pT4 97 42 100 39
Lymph node statusd
pN0 67 9 < 0.001c 67 10 < 0.001c
pN1 to pN3 76 41 80 35
Histological grade
G1 and G2 81 23 0.008c 83 19 0.002c
G3 64 30 66 29
Histological type
Ductal 120 46 0.376 122 40 0.474
Lobular 11 4 12 5
Other 15 3 16 3
Tumour focality
Unifocal 127 44 0.158 130 39 0.082
Multifocal 18 9 19 9
Oestrogen receptor
Negative (IRSe ≤ 2) 38 16 0.351 38 16 0.101
Positive (IRS > 2) 79 25 83 22
Progesterone receptor
Negative (IRSe ≤ 2) 81 32 0.214 85 32 0.056
Positive (IRS > 2) 40 11 40 8
Her2 status
Negative (IHC: 0; 1+) 101 38 0.840 105 33 0.445
Positive (IHC: 2+; 3+) 23 9 23 9
EDN3 expression
Low (IRSe < 8) 67 28 0.167 68 28 0.022c
High (IRS ≥ 8) 79 25 82 20
aOnly female patients with primary invasive breast cancer were included. bLog-rank test. cSignificant data. dAccording to the UICC (Union 
Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].eImmunoreactivity score (IRS) according to Remmele and 
Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.Available online http://breast-cancer-research.com/content/11/3/R34
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coincide with downregulation of EDN3 in breast cancer cell
lines.
Methylation of the EDN3 promoter in breast cancer cell 
lines
Since promoter hypermethylation is responsible for transcrip-
tional silencing of important tumour suppressor genes in vari-
ous human cancer types [30], we searched all three EDN
genes for the presence of CpG islands in their promoter
region. A region of high CpG density in the EDN3 nucleotide
sequence was identified as a CpG island (Figure 4a), whereas
the CpG density in EDN1 and EDN2 is lower and does not
define a CpG island under the selected criteria. To analyse the
methylation status of the EDN3 CpG promoter (Figure 4b), we
performed MSP with DNA after bisulphite treatment from non-
malignant human tissues and three non-malignant and four
malignant breast cell lines. The utilised MSP primers were
tested on a dilution series of poly-methylated DNA, which
revealed a sensitivity of 0.01 (1%) in detecting methylated
EDN3  DNA molecules in a background of unmethylated
EDN3 DNA molecules (Figure 4c). We observed no methyla-
tion of the EDN3 promoter in HMEC cells, human placental
tissue, peripheral blood lymphocytes (Figure 4c) or non-malig-
nant MCF10A cells (Figure 4e). A weak methylation signal was
detected in non-malignant MCF12A cells. Of the malignant
breast cell lines, MDA-MB231 and MCF7 harboured a meth-
ylated EDN3 promoter. In BT20 cells, both unmethylated and
methylated EDN3 promoter sequences could be detected,
whereas EDN3 was unmethylated in SKBR3 cells. Next, we
analysed the association between EDN3 expression and pro-
moter methylation in six breast cell lines by in vitro demethylat-
ing their DNA and assessing EDN3 mRNA expression after
the treatment. A clear conversion of methylation could be
observed in cell lines that were originally methylated in the
EDN3 promoter region (that is, in MDA-MB231 and MCF7
cells) (Figure 4e), resulting in 47-fold and 28-fold increases,
respectively, in EDN3 mRNA expression (Figure 4f). In BT20
cells, however, the demethylating effect was weaker and led to
a 3-fold induction of EDN3 transcription. In weakly methylated
MCF12A cells, the conversion of methylated alleles induced
EDN3 expression by 5-fold, whereas no substantially altered
change of EDN3 expression could be detected in unmethyl-
ated MCF10A (1.6-fold) or SKBR3 (1.0-fold) cells.
Frequent EDN3 promoter methylation in primary breast 
carcinomas
Next, we analysed EDN3  promoter methylation in primary
breast cancer as well. In total, 89 of 128 breast carcinoma
samples (69.5%) showed EDN3  promoter methylation (for
example, #5 in Figure 5a). The remaining breast carcinoma
samples (39 of 128; 30.5%) were not affected by this epige-
netic modification (for example, #13 in Figure 5b). None of the
17 normal breast tissues exhibited EDN3 promoter methyla-
tion. Cancerous tissues yielded a PCR product with primers
specific for the unmethylated EDN3 promoter sequence in all
cases, due to non-malignant contaminants (stromal cells and
Table 6
Multivariate Cox regression analysis of clinicopathological factors potentially influencing breast cancer-specific survival, including 
EDN3 protein expression
Variable Value P value Hazard ratio (HR) 95% confidence interval of HR
Lower Upper
Age
Continuous 0.005a 1.04a 1.01a 1.06a
pT
pT1 0 1.00
pT2 to pT4 1 0.109 1.87 0.87 4.04
pN
pN0 0 1.00
pN1 to pN3 1 0.002a 3.12a 1.53a 6.33a
Grade
G1 and G2 0 1.00
G3 1 0.013a 2.17a 1.18a 3.99a
EDN3 expression
High 0 1.00
Low 1 0.025a 1.98a 1.09a 3.61a
The variables were categorised according to Tables 4 and 5, except for age (continuous). aSignificant data. EDN3, endothelin-3.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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endothelial cells) present in the bulk tumour tissue, as has also
been described by Suzuki and colleagues [31].
We next aimed to analyse whether EDN3 promoter methyla-
tion was associated with EDN3 mRNA expression in these tis-
sues. For 71 breast cancer specimens, both EDN3
methylation and EDN3 mRNA expression have been investi-
gated in parallel. Figure 5b shows the distribution of EDN3
mRNA expression among these two groups. While carcinoma
samples with unmethylated EDN3 promoter exhibited similar
EDN3 mRNA expression as compared with normal breast tis-
sues (Figure 1e), breast carcinomas with EDN3 methylation
exhibited a significant downregulation of EDN3 mRNA expres-
sion as compared with EDN3  unmethylated samples (P =
0.005, Mann-Whitney U test).
Finally, we asked whether EDN3 promoter methylation may be
of clinical relevance in human breast cancer, as we have pre-
viously found for EDN3 protein expression. In a univariate anal-
ysis, the EDN3 methylation status in breast carcinomas was
not associated with patient age at diagnosis, tumour size,
lymph node metastasis, histological grade, histological type or
oestrogen or progesterone receptor positivity (Table 7). In
contrast to EDN3 protein expression, EDN3 promoter methyl-
ation was significantly associated neither with patient CSS (P
= 0.703) nor with patient DFS (P = 0.632) (data not shown).
Discussion
The involvement of EDNs in tumourigenesis has been
described in several reports [4,10,15]. In contrast to the
potentially oncogenic role of EDN1 and EDN2, there is still lit-
tle knowledge about the role of EDN3 in cancer initiation or
progression. A recent study demonstrated abundant expres-
Figure 3
Endothelin (EDN) mRNA expression analysis in breast cell lines Endothelin (EDN) mRNA expression analysis in breast cell lines. (a) Alignment of the primary amino acid (aa) structure of human EDN1, EDN2 and 
EDN3 after post-translational cleavage to the biologically active 21-aa form [4]. The secondary structure consists of single α-helices containing two 
disulphide bonds that hold them in a conical spiral shape, joining cysteins at positions 1–15 and 3–11 [53]. EDN3 structure differs mainly in the 
NH2-terminal region from the structure of EDN1 and EDN2. This region forms a bulge out of the basic EDN structure and has been reported to rep-
resent a major domain for binding specificity to EDN receptors and thus is critical in endothelin signalling activity [29]. Numbers indicate consecutive 
aa residues, and aa residues are indicated in universal single-letter aa code. (b) Real-time polymerase chain reaction comparing EDN3 expression 
with EDN1 and EDN2 expression. While EDN1 is overexpressed in cancerous breast cell lines (MCF7, SKBR3, MDA-MB231 and BT20), EDN3 
expression is abrogated in the same malignant cells as compared with MCF12A cells (set to 1 in each diagram).Available online http://breast-cancer-research.com/content/11/3/R34
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Figure 4
EDN3 promoter methylation analysis in breast cell lines EDN3 promoter methylation analysis in breast cell lines. (a) Prediction of CpG islands in EDN family genes. A 2-kb genomic nucleotide sequence of 
EDN1, EDN2 and EDN3 was analysed with MethPrimer software [25]. A region of particularly high CpG density (red vertical bars) in the EDN3 
nucleotide sequence proximal to the transcription start site (TSS) was identified as a CpG island (blue shaded). (b) Schematic representation of the 
EDN3 gene fragment that has been analysed for methylation. Arrows indicate hybridisation sites of methylation-specific polymerase chain reaction 
(MSP) primers, +1 indicates TSS, and vertical bars depict CpG dicnucleotides. (c) A dilution series of in vitro poly-methylated DNA with unmethyl-
ated DNA demonstrates the sensitivity of the applied MSP primers, which detect at least 1% of methylated DNA (M) in a background of unmethyl-
ated DNA in MSPs. (d) The EDN3 promoter is unmethylated in HMEC and non-malignant tissues. (e) EDN3 methylation analysis in breast cancer 
cell lines before (-) and after (+) treatment with demethylating (DAC) and histone reacetylating (TSA) drugs. In cell lines originally showing methyl-
ated EDN3 promoter alleles (MCF12A, MDA-MB231, MCF7 and BT20), a conversion of methylation was achieved as indicated by a gain of signal 
strength for non-methylation (U) and loss of signal strength for methylation (M), whereas in originally unmethylated cells (MCF10A and SKBR3), the 
treatment showed no effect. (f) EDN3 mRNA expression analysis as determined by real-time polymerase chain reaction before (-) and after (+) the 
demethylating treatment illustrates strong re-expression in those cell lines that were substantially demethylated (MCF7: 28-fold; MDA-MB231: 47-
fold) as compared with cell lines showing weaker demethylation (BT20: 3-fold; MCF12A: 5-fold) or unmethylated cells (MCF10A: 1.6-fold; SKBR3: 
1.0-fold). bp, base pairs; CpG, cytosine-phosphate-guanine dinucleotide; DAC, 5-aza-2'-deoxycytidine; EDN, endothelin; GC, guanine-cytosine con-
tent; HMEC, human mammary epithelial cells; PBL, peripheral blood lymphocyte; Plac, placental tissue; TSA, trichostatin A.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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sion of EDN1 and EDN2 but complete absence of EDN3
expression in a representative set of human breast cancer cell
lines [12]. Because we have previously found that EDN3
mRNA expression is downregulated in primary breast carcino-
mas as compared with normal breast tissues [27,28], we
aimed in this report to provide the first comprehensive analysis
of EDN3 expression and its potential implication in human
breast cancer.
Initially, we screened various non-malignant epithelial tissues
for EDN3 mRNA expression and also analysed its expression
using a breast cancer cDNA dot blot array. Besides abundant
expression in several human tissues, EDN3  was strongly
expressed in normal breast samples, providing evidence for a
functional role in epithelial tissues such as the mammary gland.
In contrast, most matched breast carcinomas showed dimin-
ished EDN3 mRNA expression both on the cDNA dot blot
Figure 5
EDN3 promoter methylation in primary breast cancer EDN3 promoter methylation in primary breast cancer. (a) Methylation-specific polymerase chain reaction (MSP) was performed on bisulphite-treated 
DNA from breast carcinomas (T) and matching normal breast tissue (N). Representative MSP results from eight patients are shown. MSP controls 
were commercially available poly-unmethylated (poly-U) or in vitro poly-methylated (poly-M) DNA. (b) Box plot demonstrating the significant associa-
tion between EDN3 promoter methylation and EDN3 mRNA expression in these tissues. For 71 samples, EDN3 expression has been assessed in 
parallel to EDN3 promoter methylation. EDN3-methylated tumours show significant downregulation as compared with EDN3-unmethylated tumours 
(P = 0.005, Mann-Whitney U test). Horizontal lines indicate group medians, and boxes indicate 25% to 75% quartiles, range, peak and minimum. 
EDN3, endothelin-3; M, methylated; U, unmethylated.Available online http://breast-cancer-research.com/content/11/3/R34
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array and by real-time PCR analysis. This finding supports the
current evidence that EDN3 may exert a functional role diver-
gent to that of EDN1/EDN2 in the human mammary gland
[18]. A further TMA analysis revealed that EDN3 protein is
abundantly expressed in normal breast whereas its expression
is reduced in a large fraction of breast carcinomas. Frequency
differences may arise due to the use of different techniques
(real-time PCR versus IHC) on separate tumour cohorts (fresh
frozen versus FFPE) and accomplishing different scoring sys-
tems. Loss of EDN3 protein expression was not associated
with relevant clinicopathological factors. For instance, it
occurred with almost equal frequency among all tumour sizes
(pT1 to pT4), suggesting that it may be an early event in the
development of infiltrating breast carcinoma. Since EDN3 is
thought to counterbalance the effects mediated by EDN1 and
EDN2 [4,18], we propose that loss of EDN3 expression could
actively enhance overexpression of the ET-axis. Recently,
upregulation of ET-axis members was found to be associated
with higher histological grade, lymph node metastasis and lym-
phovascular invasion in breast cancer [5] and also with
advanced tumour progression in ovarian cancer [32], prostate
cancer [33], Ewing sarcoma and neuroblastoma [11]. A sys-
tematic expression analysis on larger breast carcinoma
cohorts and metastatic deposits is now required, including all
three EDNs and EDNRA/EDNRB. This will unravel in detail the
inter-relationship between EDN3 expression loss and upregu-
Table 7
Clinicopathological parameters in relation to EDN3 promoter methylation
Variables EDN3 promoter
Numbera Unmethylated (percentage) Methylated (percentage) P valueb
Total 128 39 (30.5) 89 (69.5)
Clinicopathological factors
Age at diagnosis
≤ 59 years 64 22 (34) 42 (66) 0.443
> 59 years 64 17 (29) 47 (71)
Tumour sizec
pT1 44 15 (34) 29 (66) 0.680
pT2 to pT4 72 21 (29) 51 (71)
Lymph node statusc
pN0 57 16 (28) 41 (72) 0.676
pN1 to pN3 51 17 (33) 34 (67)
Histological grade
G1 and G2 68 18 (26) 50 (74) 0.310
G3 49 18 (37) 31 (63)
Histological type
Ductal 103 32 (31) 71 (69) 0.849
Lobular 15 5 (33) 10 (67)
Other 6 1 (17) 5 (83)
Immunohistochemistry
Oestrogen receptor
Negative (IRSd ≤ 2) 33 11 (33) 22 (67) 0.655
Positive (IRS > 2) 85 24 (28) 61 (72)
Progesterone receptor
Negative (IRSd ≤ 2) 33 11 (33) 22 (67) 0.655
Positive (IRS > 2) 85 24 (28) 61 (72)
aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union 
Internationale contre le Cancer): TNM Classification of Malignant Tumours [19]. dImmunoreactivity score (IRS) according to Remmele and 
Stegner [24]. EDN3, endothelin-3.Breast Cancer Research    Vol 11 No 3    Wiesmann et al.
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lation of EDN1/2 and EDNRA/B as well as its association with
breast tumour progression. In our study, loss of EDN3 expres-
sion was associated with adverse patient outcome. So far,
overexpressions of EDN1 and EDNRA were already reported
as being associated with impaired survival in breast cancer
[5,34]. Our findings support the view that an imbalanced ET-
axis is of pivotal relevance in breast cancer biology and that
EDN3, unlike other members of the ET-axis, may represent a
novel tumour suppressor gene in the human mammary gland.
Addressing the molecular cause by which EDN3 expression
becomes abrogated, we found that the EDN3 gene promoter,
unlike EDN1 and EDN2, contains a CpG island as a potential
substrate to aberrant hypermethylation and consequently
gene inactivation. Indeed, we detected EDN3 promoter meth-
ylation in cancerous breast cell lines in functional association
with loss of EDN3 mRNA expression. Moreover, a hypermeth-
ylated EDN3 promoter was also detected in 70% of breast
carcinoma specimens in significant association with loss of
EDN3 expression. We therefore conclude that aberrant EDN3
methylation is a tumour-specific event and the predominant
mechanism leading to EDN3 expression loss in breast cancer.
However, it remains elusive why patient survival was not asso-
ciated with EDN3 methylation as it was with loss of EDN3 pro-
tein expression. In fact, only very few studies detected such
outcome association on both molecular levels (for example, for
SFRP1 [22,35] or ITIH5 [36]), probably due to considerable
sensitivity differences of the available detection techniques as
well as further genetic or epigenetic alterations contributing to
the loss of a gene's expression. Interestingly, EDNRB was pre-
viously described to be methylated in numerous tumour enti-
ties, such as lung, colon, prostate, bladder, kidney, liver,
oesophageal, nasopharyngeal cancer and leukemia [37-45],
but to the authors' knowledge, never in gynaecological
tumours. So far, there has been no evidence that EDNRB
becomes methylated in breast carcinomas since a previous
study demonstrated strong EDNRB expression in all invasive
ductal carcinoma samples and in all analysed cancerous
breast cell lines [4]. Notably, an ET-axis expression pattern
similar to that of breast cancer was recently found in cervical
cancer; that is, upregulation of EDN1, EDN2, EDNRA and
EDNRB expression was accompanied by downregulation of
EDN3 expression in cancerous cervix as compared with nor-
mal cervical epithelium [46]. This suggests that a decrease of
EDN3 expression accompanied by an increase of EDNRB
expression may be a particular feature of gynaecological
tumour entities.
Since the ET-axis represents crucial decisive elements for the
direction of tumour growth, invasion and neo-angiogenesis, it
provides a promising intervention point for molecular targeted
therapies. EDNR antagonists have been proven as potent and
specific ET-axis inhibitors that block cellular pathways impli-
cated in tumour growth. The drug bosentan, which targets
both EDNRA and EDNRB, inhibits tumour growth, vascularisa-
tion and bone metastasis in breast cancer [47]. Atrasenatan,
targeting EDNRA, is capable of inhibiting proliferation and
cancer growth-promoting processes [48,49]. In addition,
blockers of EDNRA resensitised cancer cells to paclitaxel-
induced apoptosis, as observed in ovarian, prostatic, cervical
and nasopharyngeal cancer cell lines [49-51] as well as in pri-
mary ovarian and breast cancer [5,52]. Our study adds a novel
aspect to therapeutically targeting the ET-axis in breast can-
cer. Since the epigenetic lock of the EDN3 gene is potentially
reversible by DNA methyltransferase (DNMT) or histone
acetyltransferase (HDAC) inhibitors or both, these drug
classes may provide a future option in a combined treatment
consisting of a decrease in EDN1/2 signalling by blocking
EDNRs together with the reactivation of EDN3 expression by
DNMT and HDAC inhibitors. Apparently, molecular rebalanc-
ing of the ET-axis in cancerous cells may be most efficiently
achieved by targeting all deregulated axis molecules.
Conclusions
In summary, our study contributes to the understanding of
deregulated EDN signalling commonly observed in human
tumours. EDN3 expression, in contrast to abundant EDN1 and
EDN2 expression, becomes frequently inactivated by pro-
moter methylation in human breast cancer, potentially causing
aberrant activation of the ET-axis, which in turn may promote
this disease. We therefore conclude that EDN3 may be an
interesting future target for an epigenetic therapy. Forced
EDN3 re-expression by DNA demethylation agents in conjunc-
tion with inhibitors of EDNRs may rebalance ET-axis-mediated
cellular signalling to a more normal status, thus having a ther-
apeutic impact in human breast cancer.
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